Primary pharmacological therapy of patients with acromegaly with depot somatostatin analogues can be effective, both in terms of GH and IGF-1 control and in reducing tumour volume.12–16 In general, these series report biochemical success rates (achievement of a GH value < 2·5 μg/l and a normal IGF-1 level) that range between 40% and 70%. Here, IGF1 is linked to acromegaly.